Safety study of NMS-01 for mild to moderate Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a new treatment called NMS-01 for people with mild to moderate Alzheimer's disease. It aims to see if it's safe and may help with symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 85 years old.
- You have a diagnosis of probable Alzheimer's disease and a positive PET scan confirming it.
- Your dementia severity is mild to moderate (scored 1 or 2 on a standard scale).
- You have been on the same Alzheimer's medications (if any) for at least 3 months.
- You have a caregiver who can accompany you to visits and help answer questions.
- You are able to communicate any discomfort during the procedure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, NBI-1117567, for people with mild to moderate Alzheimer's disease who are already taking a standard Alzheimer's medication. The goal is to see if the new drug can help improve symptoms.
This trial tests a new investigational drug, BMS-986446, given as a single dose to healthy volunteers and multiple doses to people with early Alzheimer's disease. It aims to understand how the drug moves in the body, its safety, and whether it triggers an immune response, which could help guide future treatment for Alzheimer's.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
This study tests a new medicine, NVP-NK4146, for people with mild cognitive impairment (MCI) due to Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease. It aims to see if the drug is safe and can help slow memory decline.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.